EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, TDS Pharm Co's enterprise value is ₩37,752 Mil.
TDS Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 was ₩2,169 Mil. Therefore, TDS Pharm Co's EV-to-EBITDA for today is 17.41.
The historical rank and industry rank for TDS Pharm Co's EV-to-EBITDA or its related term are showing as below:
XKRX:464280'
s EV-to-EBITDA Range Over the Past 10 Years
Min: 5.91 Med: 10.72 Max: 26.7
Current: 17.41
During the past 5 years, the highest EV-to-EBITDA of TDS Pharm Co was 26.70. The lowest was 5.91. And the median was 10.72.
XKRX:464280's EV-to-EBITDA is ranked worse than 55.23% of 726
companies
in the Drug Manufacturers industry
Industry Median: 14.35
vs XKRX:464280: 17.41
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio (TTM).
TDS Pharm Co EV-to-EBITDA Historical Data
The historical data trend for TDS Pharm Co's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of TDS Pharm Co's EV-to-EBITDA
For the Drug Manufacturers - General subindustry, TDS Pharm Co's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
TDS Pharm Co's EV-to-EBITDA Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, TDS Pharm Co's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where TDS Pharm Co's EV-to-EBITDA falls into.
TDS Pharm Co's current Enterprise Value is ₩37,752 Mil.
TDS Pharm Co's EBITDA for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩2,169 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
TDS Pharm Co (XKRX:464280) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
TDS Pharm Co's PE Ratio (TTM) for today is calculated as:
TDS Pharm Co's share price for today is ₩11270.00.
TDS Pharm Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₩363.000.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio (TTM).
Thank you for viewing the detailed overview of TDS Pharm Co's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
TDS Pharm Co Ltd is engaged in the development and manufacturing of the Transdermal Drug Delivery System (TDDS), which is growing as a high-growth business sector in the field of drug delivery systems (DDS). The Transdermal Drug Delivery System (TDDS) is a drug delivery system that delivers drugs through the skin at a controlled speed. It has the advantages of increasing patient compliance with drugs, maximizing efficacy and effectiveness, such as minimizing side effects in the liver and digestive organs, controlling absorption rate, controlling discontinuation, controlling effective blood concentration, and enabling long-term continuous administration, and reducing burden compared to oral and injection drugs.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
XKRX:464280 has been successfully added to your 